Awaiting development: Guidance and quality standards
Showing 1 to 1 of 1
| Title | Type |
|---|---|
| Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387] | Technology appraisal guidance |
| Title | Type |
|---|---|
| Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387] | Technology appraisal guidance |